171 related articles for article (PubMed ID: 21320002)
1. New nucleoside analogs for patients with hematological malignancies.
Robak T
Expert Opin Investig Drugs; 2011 Mar; 20(3):343-59. PubMed ID: 21320002
[TBL] [Abstract][Full Text] [Related]
2. Older and new purine nucleoside analogs for patients with acute leukemias.
Robak P; Robak T
Cancer Treat Rev; 2013 Dec; 39(8):851-61. PubMed ID: 23566572
[TBL] [Abstract][Full Text] [Related]
3. Tyrosine kinase inhibitors as potential drugs for B-cell lymphoid malignancies and autoimmune disorders.
Robak T; Robak E
Expert Opin Investig Drugs; 2012 Jul; 21(7):921-47. PubMed ID: 22612424
[TBL] [Abstract][Full Text] [Related]
4. New nucleoside analogs in the treatment of hematological disorders.
Szafraniec SI; Stachnik KJ; Skierski JS
Acta Pol Pharm; 2004; 61(3):223-32. PubMed ID: 15481249
[TBL] [Abstract][Full Text] [Related]
5. Rituximab for chronic lymphocytic leukemia.
Robak T
Expert Opin Biol Ther; 2012 Apr; 12(4):503-15. PubMed ID: 22369284
[TBL] [Abstract][Full Text] [Related]
6. Nelarabine: a novel purine antimetabolite antineoplastic agent.
Buie LW; Epstein SS; Lindley CM
Clin Ther; 2007 Sep; 29(9):1887-99. PubMed ID: 18035189
[TBL] [Abstract][Full Text] [Related]
7. Novel purine nucleoside analogues for hematological malignancies.
Korycka A; Lech-Marańda E; Robak T
Recent Pat Anticancer Drug Discov; 2008 Jun; 3(2):123-36. PubMed ID: 18537755
[TBL] [Abstract][Full Text] [Related]
8. Purine nucleoside analogs as immunosuppressive and antineoplastic agents: mechanism of action and clinical activity.
Robak T; Lech-Maranda E; Korycka A; Robak E
Curr Med Chem; 2006; 13(26):3165-89. PubMed ID: 17168705
[TBL] [Abstract][Full Text] [Related]
9. Emerging immunological drugs for chronic lymphocytic leukemia.
Robak P; Smolewski P; Robak T
Expert Opin Emerg Drugs; 2015 Sep; 20(3):423-47. PubMed ID: 26153226
[TBL] [Abstract][Full Text] [Related]
10. Potential breakthroughs with investigational drugs for hairy cell leukemia.
Robak T; Wolska A; Robak P
Expert Opin Investig Drugs; 2015; 24(11):1419-31. PubMed ID: 26329588
[TBL] [Abstract][Full Text] [Related]
11. ENMD-2076 for hematological malignancies.
How J; Yee K
Expert Opin Investig Drugs; 2012 May; 21(5):717-32. PubMed ID: 22397360
[TBL] [Abstract][Full Text] [Related]
12. Current and emerging therapies for acute myeloid leukemia.
Robak T; Wierzbowska A
Clin Ther; 2009; 31 Pt 2():2349-70. PubMed ID: 20110045
[TBL] [Abstract][Full Text] [Related]
13. Lenalidomide in lymphomas and chronic lymphocytic leukemia.
Wiernik PH
Expert Opin Pharmacother; 2013 Mar; 14(4):475-88. PubMed ID: 23356486
[TBL] [Abstract][Full Text] [Related]
14. Emerging antibody-drug conjugates for treating lymphoid malignancies.
Wolska-Washer A; Robak P; Smolewski P; Robak T
Expert Opin Emerg Drugs; 2017 Sep; 22(3):259-273. PubMed ID: 28792782
[TBL] [Abstract][Full Text] [Related]
15. Potential role of novel nucleoside analogs in the treatment of acute myeloid leukemia.
Faderl S; Gandhi V; Kantarjian HM
Curr Opin Hematol; 2008 Mar; 15(2):101-7. PubMed ID: 18300755
[TBL] [Abstract][Full Text] [Related]
16. Clofarabine and nelarabine: two new purine nucleoside analogs.
Gandhi V; Plunkett W
Curr Opin Oncol; 2006 Nov; 18(6):584-90. PubMed ID: 16988579
[TBL] [Abstract][Full Text] [Related]
17. The role of clofarabine in hematologic and solid malignancies--development of a next-generation nucleoside analog.
Faderl S; Gandhi V; Keating MJ; Jeha S; Plunkett W; Kantarjian HM
Cancer; 2005 May; 103(10):1985-95. PubMed ID: 15803490
[TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetic evaluation and therapeutic activity of bendamustine in B-cell lymphoid malignancies.
Korycka-Wołowiec A; Robak T
Expert Opin Drug Metab Toxicol; 2012 Nov; 8(11):1455-68. PubMed ID: 22970741
[TBL] [Abstract][Full Text] [Related]
19. Clofarabine for myelodysplastic syndromes.
Tiu RV; Traina F; Sekeres MA
Expert Opin Investig Drugs; 2011 Jul; 20(7):1005-14. PubMed ID: 21591997
[TBL] [Abstract][Full Text] [Related]
20. New nucleoside analogs in the treatment of solid tumors.
Szafraniec SI; Stachnik KJ; Skierski JS
Acta Pol Pharm; 2004; 61(4):297-305. PubMed ID: 15575597
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
